### Asparaginase

**Section:** 8. Immunomodulators and antineoplastics ➤ 8.2. Antineoplastics and supportive medicines ➤ 8.2.1. Cytotoxic medicines

#### Indication
Unspecified malignant neoplasms of ill-defined or unspecified sites  

#### Medicine type
Biological agent

#### List type
Complementary

#### Formulations
Powder for injection: 10,000 IU in vial.

#### EML status history
- First added in 1993 (TRS 850)
- Changed in 2007 (TRS 950)
- Removed in 2015 (TRS 994)

#### Sex
All

#### Age
Also recommended for children

#### Therapeutic alternatives
The recommendation is for this specific medicine

#### Patent information
Patents have expired in most jurisdictions  
Read more about patents.

#### Tags
Cancer, Biological

#### Wikipedia
[Asparaginase](https://en.wikipedia.org/wiki/Asparaginase)

#### DrugBank
[Asparaginase](https://www.drugbank.ca/drugs/DB00784)

---

**Summary of evidence and Expert Committee recommendations**

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of asparaginase was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for asparaginase for more information.